A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

NCT06246110 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: EIK1001
DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Eikon Therapeutics